The FDA has been playing a rough game of "Whack-A-Mole" lately, smacking down would-be drugs in the fields of obesity, diabetes and psychiatry, and hitting the stocks of companies like VIVUS (Nasdaq:VVUS), Arena Pharmaceuticals (Nasdaq:ARNA) and Alexza (Nasdaq:ALXA). With a very aggressive pre-panel meeting review, investors are now extremely nervous that the agency is about to do the same to MELA Sciences (Nasdaq:MELA) and MelaFind, the company's would-be testing device for melanoma (a very serious type of skin cancer).

9 Simple Investing Ratios You Need To Know

A Consummate Binary Event
For investors who are not familiar with the term "binary event", the FDA's ultimate decision on MelaFind is a very good working definition. While large medical device companies like Stryker (NYSE:SYK) or Medtronic (NYSE:MDT) need FDA cooperation to thrive, it is more of a matter of survival for MELA Sciences.

If the agency grants approval, the company will be able to enter a large field with no other comparable competitive device option. If the agency refuses to allow MELA to market this device, the company has nothing else in its bag and will effectively be a zombie company. In other words, the stock will go up a lot if the FDA approves MelaFind, or down a lot if MelaFind is rejected. Not surprisingly, then, there has been a huge amount of stock shorting interest and option activity going into Thursday's panel meeting.

The Story So Far
The path to this FDA panel meeting has not been a smooth one. The FDA originally issued a non-approvable letter to the company back in March. After this letter, the company requested (and was granted) a panel meeting to present and discuss the data supporting this device.

Now, as part of the normal pre-meeting procedures, the FDA has posted its review of the device and it is not encouraging. It is not unusual for the FDA to play the role of devil's advocate in these reviews (in fact, it is really part of their job), but the review on MelaFind was unusually harsh. As part of the review, the FDA commented that the benefits of the device were unproven and that it had the potential to actually cause harm. Moreover, the FDA suggested that the company should do further studies to prove the efficacy and utility of the device. (For related reading, check out FDA Makes Intermune Sick.)

As that comment suggests, the data is what matters here. Unfortunately, the data is not exactly clear. Clinical studies of MelaFind have shown 98% sensitivity, and that is not too bad (though it does suggest that the device will miss about two of every 100 potentially cancerous lesions it scans). It is also worth noting that all lesions examined in the study were initially flagged as potentially cancerous, so bears have argued that the device already had a "positive bias" going for it. Moreover, trial data has shown a specificity of 9-10% and that could be problematic as well.

While the company has talked about MelaFind as a device that could increase the diagnostic confidence of dermatologists and lead to lower biopsy rates, that sort of specificity could actually lead to more biopsies. More biopsies are not necessarily a horrible thing (they are rarely painful or disfiguring and melanoma is not a disease to be trifled with), but docs could simply do more biopsies without the machine. Moreover, there was a 7% failure rate in one trial, meaning that 7% of the scans did not work for some reason. While that sounds more like a commercial issue than a regulatory problem, it is nevertheless more ammunition for a safety-obsessed FDA. (For related reading, see A Checklist For Successful Medical Technology Investment.)

The Bottom Line
It is difficult to recall the last medical device approval process that garnered so much controversy and attention, and this whole process has been strange. Here a company chose to raise money before a panel meeting (although there is an argument to be made that companies cannot always pick and choose the "when"), and the company has been rather aggressive in its rebuttals of the FDA's concerns. While that may seem like a normal human reaction for people who are committed to this device, the FDA can always punch back harder than any one company, so it may not be the best tactic. (For related reading, see FDA To Obesity Drugs: Drop Dead.)

For investors, there is almost nothing left to do but take a position (or step to the sideline) and wait for the FDA's verdict. Given the extreme conservatism of the FDA recently, it is hard to have confidence that the panel will be supportive of this device and that the FDA will grant approval. Nevertheless, the company still has a fighting chance and the large potential commercial opportunity of this device will no doubt have many investors hanging on to their shares and hoping for the best both during the panel and in the FDA's ultimate response.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing

    Build a Retirement Portfolio for a Different World

    When it comes to retirement rules of thumb, the financial industry is experiencing new guidelines and the new rules for navigating retirement.
  2. Investing

    Redefining the Stop-Loss

    Using Stop-losses for trading doesn’t mean ‘losing money’, but instead think about the money you'll start saving once you learn how they work.
  3. Fundamental Analysis

    10 Major Companies Tied to the Apple Supply Chain

    Apple has one of the best supply-chain models. Here are some of the top businesses involved, and the benefits and challenges for all.
  4. Term

    What are Non-GAAP Earnings?

    Non-GAAP earnings are a company’s earnings that are not reported according to Generally Accepted Accounting Principles.
  5. Mutual Funds & ETFs

    ETF Analysis: PowerShares FTSE RAFI US 1000

    Find out about the PowerShares FTSE RAFI U.S. 1000 ETF, and explore detailed analysis of the fund that invests in undervalued stocks.
  6. Options & Futures

    Use Options to Hedge Against Iron Ore Downslide

    Using iron ore options is a way to take advantage of a current downslide in iron ore prices, whether for producers or traders.
  7. Stock Analysis

    Fortinet: A Great Play on Cybersecurity

    Discover how a healthy product mix, large-business deal growth and the boom of the cybersecurity industry are all driving Fortinet profits.
  8. Stock Analysis

    2 Catalysts Driving Intrexon to All-Time Highs

    Examine some of the main reasons for Intrexon stock tripling in price between 2014 and 2015, and consider the company's future prospects.
  9. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  10. Charts & Patterns

    Understand How Square Works before the IPO

    Square is reported to have filed for an IPO. For interested investors wondering how the company makes money, Investopedia takes a look at its business.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Profit Margin

    A category of ratios measuring profitability calculated as net ...
  3. Quarter - Q1, Q2, Q3, Q4

    A three-month period on a financial calendar that acts as a basis ...
  4. Debt Ratio

    A financial ratio that measures the extent of a company’s or ...
  5. Price-Earnings Ratio - P/E Ratio

    The Price-to-Earnings Ratio or P/E ratio is a ratio for valuing ...
  6. Net Present Value - NPV

    The difference between the present values of cash inflows and ...
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  3. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  4. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>
  5. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  6. What is the difference between the return on total assets and an interest rate?

    Return on total assets (ROTA) represents one of the profitability metrics. It is calculated by taking a company's earnings ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!